Tag: RAP
ResApp Health’s takeover bid from Pfizer shaved by $53m after disappointing study results
ResApp Health’s (ASX: RAP) shares sank 30% this week after the company announced less than impressive study results on its COVID-19 cough detection app, which has resulted in $53 million being immedia...
ResApp Health unveils at-home sleep apnoea screening app
Digital health company ResApp Health (ASX: RAP) has unveiled a new smartphone app that can be used in the home to assess a person’s risk of obstructive sleep apnoea.
According to ResApp, the SleepC...
ResApp and Coviu team up to provide remote respiratory tests through telehealth platform
Digital health company ResApp Health (ASX: RAP) has inked a binding deal to integrate its ResAppDx-EU diagnostic test into Coviu’s telehealth platform to enable clinicians to perform respiratory asses...
ResApp Health locks-in Australian TGA approval for smartphone respiratory diagnostic technology in adults
ResApp Health (ASX: RAP) has finally locked-in Australian Therapeutic Goods Administration for using its smartphone-based diagnostic technology to determine respiratory disease in adults.
This late...
ResApp Health’s respiratory diagnostic test to be integrated into Australian telehealth platform
ResApp Health (ASX: RAP) has entered an agreement to have its acute respiratory diagnostic test integrated into Australia’s leading telehealth software platform Coviu.
According to ResApp, the inte...
ResApp to take part in German digital health program, secures TGA approval
Digital health company ResApp Health (ASX: RAP) has been given an operational boost by a German health program backed by pharmaceutical giants Roche and Sanofi, while also securing Therapeutic Goods A...
ResApp Health receives positive results from at-home sleep apnoea study
Digital health company ResApp Health (ASX: RAP) has updated the market with positive top-line results from its prospective, blinded at-home obstructive sleep apnoea study that included 308 patients.
...
ResApp Health can now market respiratory diagnostic technology for adults in EU
ResApp Health (ASX: RAP) has received Europe’s CE Mark approval for its latest smartphone-based respiratory disease diagnostic test for adults and children, paving the way for the company to sell the ...
ResApp gets all-clear to market respiratory disease test in Europe
Digital health innovator ResApp Health (ASX: RAP) has received a significant boost courtesy of European regulatory approval for its first commercial product, ResAppDx-EU.
The smartphone app has rec...
ResApp Health bounces back with ‘positive top-line results’ in adult respiratory disease study
ResApp Health (ASX: RAP) has reported “positive top-line results” from an adult clinical study, with the company’s smartphone app able to accurately diagnose all lower respiratory tract diseases evalu...
ResApp continues its march towards improving detection of respiratory disease
Digital health company ResApp Health (ASX: RAP) is a step closer to making history and developing a clinically-proven means of detecting a swathe of respiratory diseases – with the use of a mobile pho...
Lockheed Martin partners with ResApp Health to predict warfighter readiness
Digital health company ResApp Health (ASX: RAP) has honed in on a relationship with Lockheed Martin, as part of the Defense Advanced Research Projects Agency (DARPA) Warfighter Analytics using Smartph...
ResApp Health completes enrolment for acute respiratory disease study
Digital health company ResApp Health (ASX: RAP) is a step closer to clinically proving the capabilities of its proprietary ResAppDx app after announcing the completion of enrolment in its SMARTCOUGH-C...
ResApp achieves positive preliminary results in sleep apnoea study, respiratory disease research advances
ResApp Health (ASX: RAP) has achieved “excellent” preliminary results in its obstructive sleep apnoea trial using its smartphone application.
The company is carrying out clinical proof-of-concept s...
ResApp achieves positive results in study diagnosing respiratory illnesses using algorithms
Digital healthcare provider ResApp Health (ASX: RAP) has achieved further positive results in its Australian adult clinical study for diagnosing respiratory illnesses using its algorithms to measure c...
ResApp Health completes enrolment in SMARTCOUGH-C study
ResApp Health (ASX: RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, announced that it has completed enrolment in its ...
